Table 2.

Changes in the diabetes treatment burden questionnaire

	Week	Group that switched to omarigliptin			Group that continued daily DPP4i			Intergroup difference in adjusted mean change (95% CI)	p value
		Measurement (n)	Change from baseline/p value	Adjusted mean change from baseline (SE)	Measurement (n)	Change from baseline/p value	Adjusted mean change from baseline (SE)
Total score	0	35.4 ± 17.9 (105)			32.9 ± 16.1 (104)
	12	31.2 ± 17.3 (101)	− 4.0 ± 18.1/0.030	− 4.0 (2.3)	30.9 ± 16.1 (105)	− 2.0 ± 9.3/0.033	− 2.0 (2.3)	− 2.0 (− 6.0, 2.0)	0.33
Implementation burden score	0	16.8 ± 12.0 (105)			15.5 ± 10.8 (104)
	12	13.5 ± 11.1 (104)	− 3.2 ± 12.1/0.009	− 2.2 (1.5)	14.3 ± 10.3 (105)	− 1.2 ± 6.6/0.07	− 0.2 (1.5)	− 2.0 (− 4.7, 0.7)	0.14
Flexibility burden score	0	7.1 ± 4.7 (106)			6.4 ± 4.0 (105)
	12	5.6 ± 4.6 (105)	− 1.5 ± 5.0/0.003	− 1.6 (0.7)	5.8 ± 4.1 (105)	− 0.6 ± 4.2/0.12	− 0.8 (0.7)	− 0.8 (− 2.1, 0.4)	0.19
Blood control burden score	0	11.3 ± 5.9 (106)			11.0 ± 5.4 (105)
	12	12.2 ± 6.2 (102)	0.7 ± 7.1/0.31	0.2 (0.9)	10.9 ± 5.5 (105)	− 0.2 ± 3.8/0.58	− 0.7 (0.9)	0.9 (− 0.6, 2.5)	0.25

Data are presented as mean ± standard deviation (n) for measurements, mean ± standard deviation/intragroup p-value for change from baseline or mean (standard error (SE)) for adjusted mean change from baseline

One-sample t-tests were performed for intragroup comparisons of changes from baseline. The adjusted mean change was estimated using analysis of covariance (ANCOVA), with the treatment groups as the fixed effect and allocation factors (HbA1c and age at registration) as covariates

DPP4i dipeptidyl peptidase 4 inhibitor, CI confidence interval